Need help finding what you are looking for?
Contact Us
PUBLISHER: DelveInsight | PRODUCT CODE: 2082705
PUBLISHER: DelveInsight | PRODUCT CODE: 2082705
Human Papillomavirus 16-positive (HPV16+) Cancers - Epidemiology Forecast - 2036
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
HPV16+ Cancers Insights and Trends
- HPV 16 remains the predominant oncogenic type (>=60% in anogenital cancer sites and 44-91% in head and neck cancers). The inclusion of additional markers increases the attributable fraction of HPV 16 in vulvar, penile, oral cavity, and oropharyngeal cancers, and also confirms the causal role of other, less common mucosal HPV types.
- HPV16 status is primarily confirmed via molecular or immunohistochemical testing. p16 overexpression is widely used as a practical screening tool, especially in oropharyngeal cancers, but requires confirmation with HPV-specific assays.
- According to the Centre for Disease Control and Prevention, among all the cases of anal cancer in the United States, about 91% are thought to be attributable to be caused by HPV infection.
- According to the Centre for Disease Control and Prevention, among all the cases of anal cancer in the United States, about 91% are thought to be attributable to be caused by HPV infection.
- Most cases of cervical cancer occur as a result of infection with HPV16 and 18. Type 16 is the cause of approximately 50% of cervical cancers worldwide.
- Approximately 90% of head and neck cancers are accounted for by HNSCC, and its incidence is steadily increasing, largely due to the growing burden of HPV-positive OPSCC in developed countries. At the same time, in developing regions, continued tobacco and lifestyle exposures remain the main cause.
DelveInsight's 'HPV16+ Cancers - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the HPV16+ Cancers, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
HPV16+ Cancers Understanding and Diagnosis Algorithm
HPV16+ Cancers Overview and Diagnosis
HPV16+ cancers are virus-driven epithelial malignancies primarily caused by persistent infection with human papillomavirus type 16, one of the most oncogenic HPV strains responsible for a significant proportion of cervical cancers and head & neck squamous cell carcinomas, particularly oropharyngeal tumors. These cancers arise when viral oncoproteins E6 and E7 disrupt key tumor suppressor pathways, leading to uncontrolled cellular proliferation, genomic instability, and malignant transformation of epithelial cells.
HPV16+ Cancers Diagnosis
Diagnosis begins with clinical suspicion based on symptoms or screening findings, followed by confirmation through biopsy and histopathological examination of the suspected lesion, which typically reveals squamous cell carcinoma. Once malignancy is established, HPV16 status is determined using molecular and immunohistochemical methods, most commonly HPV DNA genotyping to directly detect viral genetic material and p16 immunohistochemistry. In some settings, HPV E6/E7 mRNA testing may also be used for more definitive evidence of active viral oncogene expression.
HPV16+ Cancers Epidemiology
Key Findings from HPV16+ Cancers Epidemiological Analysis and Forecast
- An estimated 26 million Americans have an oral HPV infection at any given time, of whom approximately 2,600 are infected with HPV16.
- The total incident cases of HPV16+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) in Japan were nearly 3,900 in 2025.
- High-risk HPV types account for nearly 5% of cancers worldwide and are predominantly associated with cervical, anogenital, and oropharyngeal malignancies. Outside these regions, HPV-associated tumors, largely driven by HPV16, remain rare and are typically reported at acral sites such as the hands and feet.
- Most cases of cervical cancer occur as a result of infection with HPV16 and 18. High-risk types, especially HPV16, are found to be highly prevalent in human populations. Type 16 is the cause of approximately 50% of cervical cancers worldwide. The infection is usually transmitted by sexual contact, causing squamous intraepithelial lesions.
Scope of the Report:
- The report covers a segment of a descriptive overview of HPV16+ cancers, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
HPV16+ Cancers Patient Population Forecast
Report Key Strengths
- Epidemiology-based (Epi-based) Bottom-up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
FAQs:
- What are the disease risks, burdens, and unmet needs of HPV16+ cancers? What will be the growth opportunities across the 7MM concerning the patient population with HPV16+ Cancers?
- What is the historical and forecasted HPV16+ cancers patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy:
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Product Code: DIEI0910
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of HPV16+ Cancers
4. Epidemiology Methodology of HPV16+ Cancers
5. HPV16+ Cancers Epidemiology Overview at a Glance
- 5.1. Patient Share (%) Distribution by Country in 2025 in the 7MM
- 5.2. Patient Share (%) Distribution by Country in 2036 in the 7MM
6. Disease Background And Overview of HPV16+ Cancers
- 6.1. Introduction
- 6.2. Causes
- 6.3. Signs And Symptoms
- 6.4. Diagnosis
- 6.4.1. Differential Diagnosis
- 6.4.2. Diagnostic Algorithm
- 6.4.3. Diagnostic Guidelines
7. Epidemiology and Patient Population of HPV16+ Cancers
- 7.1. Key Findings
- 7.2. Assumption and Rationale
- 7.3. Total Incident Cases of HPV16+ Cancers in the 7MM
- 7.4. The United States
- 7.4.1. Total Incident Cases of Selected Indications in the United States
- 7.4.2. Total Incident Cases of Selected Indications by HPV Status in the United States
- 7.4.3. Total Incident Cases of HPV16+ Cancerss in the United States
- 7.4.4. Gender-specific Incident Cases of HPV16+ Cancers in the United States
- 7.4.5. Stage-specific Incident Cases of HPV16+ Cancers in the United States
- 7.5. EU4 and the UK
- 7.5.1. Total Incident Cases of Selected Indications in EU4 and the UK
- 7.5.2. Total Incident Cases of Selected Indications by HPV Status in EU4 and the UK
- 7.5.3. Total Incident Cases of HPV16+ Cancerss in EU4 and the UK
- 7.5.4. Gender-specific Incident Cases of HPV16+ Cancers in EU4 and the UK
- 7.5.5. Stage-specific Incident Cases of HPV16+ Cancers in EU4 and the UK
- 7.6. Japan
- 7.6.1. Total Incident Cases of Selected Indications in Japan
- 7.6.2. Total Incident Cases of Selected Indications by HPV Status in Japan
- 7.6.3. Total Incident Cases of HPV16+ Cancerss in Japan
- 7.6.4. Gender-specific Incident Cases of HPV16+ Cancers in Japan
- 7.6.5. Stage-specific Incident Cases of HPV16+ Cancers in Japan
8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
Product Code: DIEI0910
List of Tables
- Table 1: Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in 7MM (2022-2036)
- Table 2: Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in 7MM (2022-2036)
- Table 3: Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in the United States (2022-2036)
- Table 4: Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in the United States (2022-2036)
- Table 5: Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in Germany (2022-2036)
- Table 6: Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in Germany (2022-2036)
- Table 7: Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in France (2022-2036)
- Table 8: Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in France (2022-2036)
- Table 9: Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in Italy (2022-2036)
- Table 10: Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in Italy (2022-2036)
- Table 11: Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in Spain (2022-2036)
- Table 12: Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in Spain (2022-2036)
- Table 13: Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in the United Kingdom (2022-2036)
- Table 14: Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in the United Kingdom (2022-2036)
- Table 15: Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in Japan (2022-2036)
- Table 16: Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in Japan (2022-2036)
List of Figures
- Figure 1 Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in 7MM (2022-2036)
- Figure 2 Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in 7MM (2022-2036)
- Figure 3 Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in the United States (2022-2036)
- Figure 4 Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in the United States (2022-2036)
- Figure 5 Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in Germany (2022-2036)
- Figure 6 Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in Germany (2022-2036)
- Figure 7 Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in France (2022-2036)
- Figure 8 Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in France (2022-2036)
- Figure 9 Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in Italy (2022-2036)
- Figure 10 Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in Italy (2022-2036)
- Figure 11 Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in Spain (2022-2036)
- Figure 12 Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in Spain (2022-2036)
- Figure 13 Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in the United Kingdom (2022-2036)
- Figure 14 Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in the United Kingdom (2022-2036)
- Figure 15 Human Papillomavirus 16-positive (HPV16+) Cancers Epidemiology in Japan (2022-2036)
- Figure 16 Human Papillomavirus 16-positive (HPV16+) Cancers Diagnosed and Treatable Cases in Japan (2022-2036)
The table of contents is not exhaustive; will be provided in the final report
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.